L

ess than two months after Nevada enacted a controversial law requiring more transparency from drug makers over their pricing of diabetes medicines, the pharmaceutical industry is pushing back.

In a lawsuit filed last Friday, two large industry trade groups claim the law is an “unprecedented and unconstitutional” action that interferes with well-established patent law by robbing drug makers of their right to protect trade secrets. Consequently, the trade groups also argue the law impedes the ability to successfully to do business in other states by tying penalties to wholesale, or list, prices.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy